The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting institutional confidence in sleep apnea treatment technologies, Nyxoah has secured $15 million in non-dilutive debt funding from the European Investment Bank. This new funding brings the total capital secured by the company in June 2026 to $110 million. According to reports, the company intends to use these funds to accelerate the commercial launch of its Genio system in the United States and scale up its manufacturing operations.
This support from the EIB comes at a time when European med-tech firms are facing intense competition to enter global markets, with Nyxoah seeking to compete against majors like Inspire Medical Systems, which reported strong revenue growth in its latest quarter per market data. Non-dilutive financing serves as a critical strategic tool for growth-stage companies, allowing expansion without diluting existing shareholder equity, a trend gaining traction amid higher borrowing costs.
Sign in to access this content
Sign InOperationally, investors are watching the U.S. commercial launch results as a primary catalyst for stock movement in the coming period. Looking at the economic calendar, healthcare sector sentiment may be influenced by upcoming European inflation data, following the ECB's interest rate decision of 2.4% on June 11, 2026. Liquidity levels and the ability to generate returns from the Genio system will remain the key benchmarks for evaluating the success of this financing round.